Tandem Diabetes Care, Inc. — 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. The filing was signed February 24, 2021. Amounts below are in U.S. dollars.
Business context
Tandem develops and sells insulin pumps, related disposable supplies, and diabetes-management software. Its t:slim X2 platform accounted for all new pump shipments. Control-IQ, its automated insulin delivery feature, launched in the U.S. in January 2020; international rollout began in the second half of the year. The company acquired Sugarmate and expanded its t:connect mobile app in 2020.
Financial and operating performance
| Metric | 2020 | 2019 |
|---|---|---|
| Sales | $498.8 million | $362.3 million |
| Gross profit / margin | $260.5 million / 52.2% | $194.2 million / 53.6% |
| Operating loss | $8.0 million | $16.7 million |
| Net loss | $34.4 million | $24.8 million |
| Operating cash flow | $24.7 million | $41.9 million |
| Capital expenditures | $27.4 million | $19.5 million |
- Sales grew by $136.5 million, or approximately 38%. U.S. sales were $415.7 million and international sales were $83.2 million.
- Worldwide pump shipments increased 24% to 90,771. Pump-related supplies benefited from a 52% increase in estimated worldwide installed customers.
- Gross margin declined 1.4 percentage points. The company cited $6.7 million in Control-IQ-related royalties, product mix, pandemic-related costs, and capacity expansion among the pressures.
- Annual net loss widened despite the smaller operating loss, chiefly because other expense rose to $28.3 million, including a $17.1 million warrant revaluation loss and $12.8 million of interest expense, largely related to the convertible notes.
- Fourth-quarter sales were $168.1 million; operating income was $18.7 million and net income was $17.0 million. The company also reported positive net income in fourth-quarter 2019 ($2.7 million).
Liquidity and debt
- At year-end, cash and cash equivalents were $94.6 million and short-term investments were $390.3 million, totaling $484.9 million. Working capital was $533.4 million.
- In May 2020, Tandem issued $287.5 million principal amount of 1.50% convertible senior notes due 2025. The notes’ year-end carrying value was $203.0 million; the company reported $244.6 million in net proceeds after debt issuance costs and capped-call costs.
- The company stated that available cash and investments were expected to fund existing operations for at least 12 months from the filing date. It also noted that growth, product development, manufacturing, and customer-support investments would increase expenses.
- Operating cash flow was positive but lower than 2019, with higher receivables and inventory contributing to working-capital use.
Material changes, outlook, and risks
- COVID-19: Management said the pandemic’s adverse sales and operating effects became more pronounced from the second quarter and would likely continue with unpredictable variability. Restrictions on in-person sales and training, delayed development work, and supplier constraints affected operations. Infusion-set inventory constraints led to some customer substitutions; management reported no expected near-term disruption to pump and cartridge production.
- Product and market outlook: Tandem planned to scale Control-IQ internationally in the first half of 2021, subject to regulatory approvals; commercialize Control-IQ in Canada in early 2021; and continue developing the t:sport pump, mobile bolus functionality, AID enhancements, and integrations with Abbott CGM and Dexcom G7. These are plans, not quantified financial guidance. No clear numerical revenue or earnings guidance is provided in the filing.
- Regulatory contingency: Australia’s Therapeutic Goods Administration suspended sales of Tandem pumps in the country beginning November 24, 2020. The company was in discussions with the regulator to lift the suspension.
- Cybersecurity and litigation: A January 2020 phishing incident may have exposed information in employee email accounts. A consolidated California class action remained pending. Tandem said it could not estimate the outcome or potential loss. A separate proposed employee wage-and-expense class action was also pending; no material loss was considered probable or reasonably estimable for the disclosed proceedings.
- Other risks: Tandem continued to report significant cumulative losses and no sustained profitability. Key exposures include dependence on t:slim X2 and related supplies, competition, reimbursement and distributor concentration, reliance on suppliers and CGM partners, regulatory requirements, and the ability to scale manufacturing while improving margins. Its two largest distributors represented 15.9% and 12.9% of 2020 sales.
- Profitability context: Management said it achieved quarterly profitability in the fourth quarter of 2020, but cautioned that it may not do so consistently. The company reported an accumulated deficit of $659.2 million.
Important facts for investors to verify
- Whether revenue growth and pump shipments continue, particularly as pandemic-related purchasing and clinical-visit disruptions change.
- Whether gross margin recovers after 2020’s royalty, product-mix, pandemic, and capacity-expansion pressures.
- Progress on international and Canadian Control-IQ launches, mobile bolus clearance, t:sport development, and Abbott/Dexcom integrations.
- Resolution and commercial impact of the Australian sales suspension, and the status and potential costs of the data-breach and employee lawsuits.
- Convertible-note terms, potential dilution or cash settlement requirements, and the company’s capacity to fund planned investment while pursuing sustained profitability.
- Supply continuity, distributor concentration, and customer-retention performance. The filing identifies warranty-reserve estimation and convertible-note valuation as critical audit matters; the auditor issued unqualified opinions on the financial statements and internal controls.